# Why researchers measured both total and free IGF-1 at birth

- Article ID: research-189
- Product: IGF-1 Human (igf-1-human-625)
- Canonical page: https://heritagebiolabs.com/research-library/articles/189-why-researchers-measured-both-total-and-free-igf-1-at-birth
- Product collection: https://heritagebiolabs.com/research-library/products/igf-1-human
- Product page: https://heritagebiolabs.com/product/igf-1-human-625
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Short amino-acid chains held together by peptide bonds can act as messengers. Human insulin-like growth factor 1 (IGF-1) is a longer, 70-residue hormone that helps regulate growth. A 2026 study measured IGF-1 and other proteins in cord blood to ask whether the amount of hormone available for signaling differed with size at birth. [1, 2]

Much of the IGF-1 in blood is carried by binding proteins. A measurement of total IGF-1 includes hormone that is bound as well as hormone that is free. Other proteins can influence this balance. Some enzymes cut IGF-binding proteins, which can change how tightly they hold the hormone. The study measured several parts of this system in full-term newborns, including IGF-1, binding proteins and related proteins that influence whether the binding proteins are cut. [1]

The researchers studied 179 newborns classified as small, appropriate or large for gestational age. Compared with the appropriate-size group, newborns who were small for gestational age had lower total and free IGF-1, lower levels of some proteins in the system and higher levels of others. One enzyme involved in regulating the system, PAPP-A2, was positively associated with birth weight and length in the study. Measurements based on the newborns' weight relative to length also identified differences in several components of the pathway. [1]

The study collected samples around birth and examined how the measurements varied across groups. That design can show that the measurements occur together. It cannot establish whether changes in the IGF system produced differences in fetal growth, whether growth or nutritional conditions produced changes in the hormone system, or whether both were influenced by another factor. The study also measured circulating blood components and did not directly observe how much hormone reached every developing tissue. [1]

This recent human evidence is about natural variation in the IGF-1 system, including the distinction between a hormone's total measured concentration and its free fraction. The investigators did not administer recombinant human IGF-1. The findings therefore do not establish what a medication containing the hormone would do to prenatal or newborn growth. [1, 2]

## Sources

1. Barrios V et al. Size in small-for-gestational-age neonates correlates with insulin-like growth factor-binding protein proteolysis and insulin-like growth factor-I bioavailability. Journal of the Endocrine Society (publication 2026-07-06). <https://pubmed.ncbi.nlm.nih.gov/42491477/>
2. Eton Pharmaceuticals, Inc. INCRELEX (mecasermin) injection, for subcutaneous use. DailyMed (label effective 2026-05-18). <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 038 - Human Relaxin-2 and IGF-1 Human.docx; article 189; content SHA-256 c3acb9e089475d28519a8bd266961b4a0816145eb63ad5010622d6ed0ff9175e.
